Immunobiotic therapeutics developer Epiva Biosciences has merged with immune-microbiome company Evelo Biosciences to develop new therapeutics for cancer, autoimmune and inflammatory diseases.

According to the transaction, the newly-formed combined company will carry the name of Evelo Biosciences and establish a definitive immuno-microbiome therapeutics platform.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Flagship Ventures has financed the combined company with approximately $40m and plans for additional investments to support the rapid growth of the company.

Nichi-iko Pharmaceuticals, through its wholly-owned subsidiary Shepard Vision INC, plans to enhance its US market to commercialise the biosimilar products pipeline and increase its presence in injectables by acquiring Sagent Pharmaceuticals.

"Cell Medica limited has acquired the remaining 73% stake in Denelex Therapeutics to become a 100% stake holder in the share capital of Denelex Therapeutics."

JPMorgan Securities Japan Co. is acting as financial advisor and Nishimura & Asahi, Paul, Weiss, Rifkind, Wharton & Garrison LLP, Hyman, Phelps & McNamara P.C. are acting as legal advisors to Nichi-Iko, while Perella Weinberg Partners LP and Morgan Stanley & Co are acting as financial advisors.

See Also:

Krikland & Ellis LLP is acting as legal advisors to Sagent for the transaction.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Cell Medica limited has acquired the remaining 73% stake in Denelex Therapeutics to become a 100% stake holder in the share capital of Denelex Therapeutics.

Pursuant to the transaction, Denelex Therapeutics will be integrated with Cell Medica’s product development programme.

The acquisition enables Cell Medica to advance the development of gene-modified immune cell products for the treatment of cancer.